The Drug-Induced Respiratory Disease Website and App

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

VI. Pulmonary vasculopathy

VI.a Pulmonary embolism - Venous thrombosis/thromboembolism

VI. Pulmonary vasculopathy

VI.u Pulmonary vascular microthrombi

II. Pulmonary edema - Acute lung injury - ARDS

II.v Acute respiratory or cardiopulmonary failure

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

X. Systemic/Distant conditions, syndromes and reactions

X.ba Rhabdomyolysis (see also under Xj)

XI. Miscellaneous

XI.g Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)

XI. Miscellaneous

XI.r Death following exposure or poisoning

XI. Miscellaneous

XI.aa CNS symptoms or involvement, stroke

XI. Miscellaneous

XI.bt Hyperemesis

XII. Cardiovascular involvement / toxicity

XII.aj Systemic arterial thrombosis

I. Interstitial/parenchymal lung disease

I.af Chemical (toxic) pneumonitis

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.j Anti-GBM-related pneumorenal syndrome and DAH (Goodpasture) or flare of

IV. Airway involvement

IV.j Bronchiolitis (a clinical-imaging pattern suggestive of)

IV. Airway involvement

IV.q Reactive airway dysfunction syndrome (RADS)

IV. Airway involvement

IV.aj Airway hemorrhage on endoscopy

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.ay Tracheal injury

XV. Pathology

XV.w Path: Pulmonary edema (see also II/IIa)

XVI. Imaging

XVI.ai Imaging: A 'tree-in-bud' pattern

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

I. Interstitial/parenchymal lung disease

I.j Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.n Pulmonary alveolar proteinosis (PAP) (secondary)

I. Interstitial/parenchymal lung disease

I.u Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.v Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.aw Persistent reduction in diffusing capacity for CO upon resolution of the adverse effect

II. Pulmonary edema - Acute lung injury - ARDS

II.t Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.m Coagulopathy

IV. Airway involvement

IV.d Cough (lone)

IV. Airway involvement

IV.k Bronchiectasis

IV. Airway involvement

IV.t Sptutum production - Bronchorrhea - 'Bronchitis'

IV. Airway involvement

IV.v Deterioration/exacerbation of preexisting asthma or COPD

IV. Airway involvement

IV.ad Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)

IV. Airway involvement

IV.al Sputum production - Bonchorrhea - ‘Bronchitis’

V. Pleural and/or pericardial involvement

V.f Pneumothorax

VII. Mediastinal involvement

VII.e Granulomatous mediastinal lymphadenopathy

VII. Mediastinal involvement

VII.h Pneumomediastinum

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.d Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.al Epiglottitis

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.an Facial/labial/buccal/oral/dental trauma

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.ap Airway foreign body

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.at Gross tracheal inflammation on endoscopy

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.aw Foreign body in the airway

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.bb Tracheitis including eosinophilic tracheal inflammation

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.bc Tracheal redness/inflammation on gross endoscopic examination

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.h Dyspnea, unexplained otherwise

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.af Seizures

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.q Systemic inflammatory response

X. Systemic/Distant conditions, syndromes and reactions

X.aq Relapse or flare of preexisting ulcerative colitis

XI. Miscellaneous

XI.ac Thermal skin/dermal injury

XI. Miscellaneous

XI.ay Chest tightness

XI. Miscellaneous

XI.bc Polycythemia

XI. Miscellaneous

XI.bd Nicotine poisoning

XI. Miscellaneous

XI.be Burns

XII. Cardiovascular involvement / toxicity

XII.ag Bradycardia

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.p Path: Exogenous lipoid pneumonia

XV. Pathology

XV.x Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XV. Pathology

XV.y Path: Respiratory bronchiolitis (w/wo the RB-ILD-pattern)

XV. Pathology

XV.ab Path: Pulmonary capillaritis

XV. Pathology

XV.bi Path: Giant-cell interstitial pneumonia (GIP)-pattern

XVI. Imaging

XVI.a Imaging: Diffuse haze

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.d Imaging: Alveolar opacities or haze with a batwing or butterfly distribution

XVI. Imaging

XVI.g Imaging: Diffuse whiteout/alveolar shadowing (see also under IIb-ARDS)

XVI. Imaging

XVI.af Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.bl Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

XVII. Infections & related conditions

XVII.a Respiratory tract infection incl. pneumonia

XVII. Infections & related conditions

XVII.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XVII. Infections & related conditions

XVII.ac Actinomycosis

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.x Eye catcher: A batwing pattern on imaging

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.b BAL: An excess proportion of neutrophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.c BAL: An excess proportion of eosinophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.d BAL: Gross or microscopic bleeding/hemorrhage

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.f BAL: Foamy macrophages

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.i BAL: Oil red O-stainable material in BAL macrophages othen than exogenous lipids

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.n BAL: Brown-pigmented macrophages

II. Pulmonary edema - Acute lung injury - ARDS

II.g Negative pressure pulmonary edema (NPPE)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.w Rapidly progressive ILD/pulmonary fibrosis (a.k.a. Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.y Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.aa Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ad Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.aj Shrinking lung syndrome

I. Interstitial/parenchymal lung disease

I.ax Chronic pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.d Pulmonary edema, cardiogenic

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.c Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

IV. Airway involvement

IV.n Obstructive airway dysfunction (see also IVc, XVx)

IV. Airway involvement

IV.y Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

IV. Airway involvement

IV.ab Exacerbation or deterioration of preexisting COPD

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.s Serositis - Polyserositis

VI. Pulmonary vasculopathy

VI.b Pulmonary arterial hypertension

VII. Mediastinal involvement

VII.a Lymphadenopathy (intrathoracic)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.t Vocal cord paresis/paralysis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.r Myasthenia gravis - Myasthenic-like syndrome

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ab Guillain-Barré (or GB-like) syndrome (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ac Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)

X. Systemic/Distant conditions, syndromes and reactions

X.c Capillary leak syndrome (CLS)

X. Systemic/Distant conditions, syndromes and reactions

X.h Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.n Tumor lysis syndrome (TLS)

X. Systemic/Distant conditions, syndromes and reactions

X.am Immune-related adverse effect/toxicity

X. Systemic/Distant conditions, syndromes and reactions

X.an Cytokine release syndrome - Cytokine storm

X. Systemic/Distant conditions, syndromes and reactions

X.aw Connective tissue disease

X. Systemic/Distant conditions, syndromes and reactions

X.ay Polymyalgia rheumatica

X. Systemic/Distant conditions, syndromes and reactions

X.bi Temporal arteritis (Horton’s)

XI. Miscellaneous

XI.n Neutropenia, agranulocytosis (w/wo infection/sepsis)

XI. Miscellaneous

XI.y Adrenal suppression

XI. Miscellaneous

XI.ag Vertebral compression fracture

XI. Miscellaneous

XI.au Graft vs. host disease in transplant recipients

XI. Miscellaneous

XI.av Deterioration of graft function in SOT recipients

XI. Miscellaneous

XI.ba Nonrespiratory AE of interest

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.e Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.g Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.l Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.r Heart failure (biventricular, congestive)

XII. Cardiovascular involvement / toxicity

XII.s Heart block (bundle branch- or AV-)

XII. Cardiovascular involvement / toxicity

XII.ai Cardiotoxicity

XII. Cardiovascular involvement / toxicity

XII.ax Necrotizing myocarditis (w/o evidence for CAD)

XII. Cardiovascular involvement / toxicity

XII.ba Sudden cardiac death

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also pattern If)

XV. Pathology

XV.e Path: ILD with a granulomatous component (see also Im)

XV. Pathology

XV.l Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

XV. Pathology

XV.v Path: Micronodular organizing pneumonia/BOOP

XV. Pathology

XV.ba Path: Granulomatous lymphadenopathy

XV. Pathology

XV.ca Path: Myocarditis

XV. Pathology

XV.co Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

XV. Pathology

XV.cp Path: Pneumocyte vacuolization

XV. Pathology

XV.cw Path: Myocardial vasculitis

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.bh Imaging: F18-PET scan positive lympadenopathy

XVI. Imaging

XVI.bm Imaging: Avid pleural uptake on PET-scan

XVI. Imaging

XVI.bt Imaging: A subsolid lung nodule or nodules

XVII. Infections & related conditions

XVII.b Opportunistic pulmonary/systemic infections

XVII. Infections & related conditions

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XVII. Infections & related conditions

XVII.q Viral pneumonia

XVII. Infections & related conditions

XVII.r Fungal infection (pulmonary/extrapulmonary)

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

I. Interstitial/parenchymal lung disease

I.ao Pulmonary infiltrates

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

XI. Miscellaneous

XI.a Cyanosis, a low SpO2 and normal measured PaO2

XI. Miscellaneous

XI.s Sniffing death - Death from inhalation of compound

XII. Cardiovascular involvement / toxicity

XII.m Cardiac- cardiorespiratory/pulmonary arrest

XII. Cardiovascular involvement / toxicity

XII.by Lead poisoning

XXIV. Veterinary medicine

XXIV.a Veterinary: Pneumonitis - Interstitial lung disease

I. Interstitial/parenchymal lung disease

I.k Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.z An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.al Silicone pneumonitis - 'Silicone lung'

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

VI. Pulmonary vasculopathy

VI.m Silicone pulmonary embolism (SE) - SE syndrome

VII. Mediastinal involvement

VII.k Mediastinal silicone infiltration/siliconoma

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.k Submucosal airway petechiae/hemorrhage

X. Systemic/Distant conditions, syndromes and reactions

X.u Multiple organ dysfunction/failure (MODS/MOF)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.bn A restrictive lung function defect

XI. Miscellaneous

XI.bo Parietal chest involvement

XV. Pathology

XV.g Path: Alveolar hemorrhage (see also IIIa)

XV. Pathology

XV.bn Path: Silicone droplets/vacuoles in lung tissue, pulmonary vasculature, or lymph nodes

XV. Pathology

XV.bo Path: Siliconoma

XV. Pathology

XV.cw Path: Silicone pulmonary embolism

XVI. Imaging

XVI.e Imaging: Pulmonary opacities with a subpleural distribution

XVI. Imaging

XVI.ax Imaging: Foreign body pulmonary embolism

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.l BAL: Silicone globules in macrophages

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.e Pulmonary hematoma

VII. Mediastinal involvement

VII.g Hemomediastinum - Mediastinal hematoma

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.b Hematoma of/around central airway wall potentially causing UAO

XI. Miscellaneous

XI.k Esophageal hematoma (may cause chest pain and/or tracheal compression)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.ba Irreversible respiratory damage requiring lung Tx

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.x ANCA positivity. Subclinical or with clinical manifestations

XV. Pathology

XV.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XV. Pathology

XV.bl Path: Resolving alveolar damage

XV. Pathology

XV.ct Path: Delayed Alveolar Injury with Delayed Epithelialization (DAIDE)

XVI. Imaging

XVI.f Imaging: Bibasilar opacities/shadowing

XVI. Imaging

XVI.bb Imaging: Pneumomediastinum

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.h Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.m ILD with a granulomatous component

XVII. Infections & related conditions

XVII.h Nontuberculous pulmonary mycobacterial infection/superinfection

XVII. Infections & related conditions

XVII.n Legionella pneumophila pneumonia